Skip to search formSkip to main contentSkip to account menu

SC 52151

Known as: SC-52151 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Urea
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1997
1997
Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151.
SC-52151, an HIV-1 protease inhibitor, was developed as an ethanol-based elixir and subsequently as a self-emulsifying drug… 
1997
1997
Supercritical fluid extraction method development for extraction of an experimental HIV protease inhibitor drug from animal feed.
1997
1997
In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease…
Protein binding can impair the potency of human immunodeficiency virus (HIV) protease inhibitors. Therefore, the activity of a… 
1995
1995
Protease inhibitors: where are they now?
Protease inhibitors block HIV by binding with its protease enzyme and it is hoped that they will be more potent and less toxic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)